Creo Medical Group PLC
LSE:CREO
Intrinsic Value
Creo Medical Group Plc operates as a medical device company that focuses on surgical endoscopy. [ Read More ]
The intrinsic value of one
CREO
stock under the Base Case scenario is
42.33
GBX.
Compared to the current market price of 34.34 GBX,
Creo Medical Group PLC
is
Undervalued by 19%.
Creo Medical Group PLC's market capitalization is 120.5m GBX.
CREO stock price is 34.34 GBX.
CREO stock price (34.34 GBX) is 19% less than its Intrinsic Value (42.33 GBX).
CREO. Open DCF Valuation
CREO stock price (34.34 GBX) is 19% less than its Relative Value (42.33 GBX). Open Relative Valuation
CREO has upside potential of 196% compared to the average analyst price target.
Open Wall St Estimates
CREO's Revenue has grown by 13% over the past 12 months.
CREO's ROE (Return on Equity) has significantly decreased in the last 3 years from -28% to -39%, and is approaching profitability.
CREO's Revenue is forecast to grow at a rate of 26% per year over the next 3 years.
CREO's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -99% to -47%, and is approaching profitability.
CREO has positive Gross Profit for the last twelve months.
CREO has negative Operating Income for the last twelve months.
CREO has negative Net Income for the last twelve months.
CREO's ROE (Return on Equity) for the past 12 months is negative and is equal to -39%.
CREO's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -47%.
CREO's Altman Z-Score is very low and is equal to 1.42.
CREO has negative Free Cash Flow for the last twelve months.
CREO's Revenue has been growing by an exceptional 1 431% per year for the last 3 years.
CREO's D/E (Debt to Equity) is very low and is equal to 0.08.
CREO has negative three-year average ROE (Return on Equity): -32%. The company is not efficient at transforming stockholders' equity into net income.
CREO has negative three-year average ROIC (Return on Invested Capital): -109%. The company is not efficient at using invested capital to generate operating income.
CREO's short-term assets (49m GBP) exceed its short-term liabilties (12m GBP).
CREO's long-term assets (89m GBP) exceed its long-term liabilties (20m GBP).
CREO has negative Net Debt. This means that the company has more cash and short-term investments (27m GBP) than debt (6m GBP).
CREO doesn't generate enough operating income (-28m GBP) to safely cover interest payments on its debt (308k GBP).
Valuation Backtest
Creo Medical Group PLC
Run backtest to discover the historical profit from buying and selling
CREO
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Creo Medical Group PLC
Balance Sheet Decomposition
Creo Medical Group PLC
| Current Assets | 49.1m |
| Cash & Short-Term Investments | 26.5m |
| Receivables | 14.6m |
| Other Current Assets | 8m |
| Non-Current Assets | 39.6m |
| Long-Term Investments | 2.1m |
| PP&E | 9.7m |
| Intangibles | 26.3m |
| Other Non-Current Assets | 1.5m |
| Current Liabilities | 11.9m |
| Accounts Payable | 7.5m |
| Other Current Liabilities | 4.4m |
| Non-Current Liabilities | 7.8m |
| Long-Term Debt | 5.6m |
| Other Non-Current Liabilities | 2.2m |
Earnings Waterfall
Creo Medical Group PLC
|
Revenue
|
29.2m
GBP
|
|
Cost of Revenue
|
-15.2m
GBP
|
|
Gross Profit
|
14.1m
GBP
|
|
Operating Expenses
|
-42.3m
GBP
|
|
Operating Income
|
-28.2m
GBP
|
|
Other Expenses
|
3.1m
GBP
|
|
Net Income
|
-25.1m
GBP
|
Free Cash Flow Analysis
Creo Medical Group PLC
What is Free Cash Flow?
CREO Profitability Score
Profitability Due Diligence
Creo Medical Group PLC's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
Creo Medical Group PLC's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
CREO Solvency Score
Solvency Due Diligence
Creo Medical Group PLC's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Creo Medical Group PLC's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CREO Price Targets Summary
Creo Medical Group PLC
According to Wall Street analysts, the average 1-year price target for
CREO
is 101.49 GBX
with a low forecast of 99.99 GBX and a high forecast of 105 GBX.
Shareholder Return
CREO Price
Creo Medical Group PLC
| Average Annual Return | -26.28% |
| Standard Deviation of Annual Returns | 39.61% |
| Max Drawdown | -92% |
| Market Capitalization | 121.1m GBX |
| Shares Outstanding | 361 476 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Creo Medical Group PLC
Country
Industry
Market Cap
Dividend Yield
Description
Creo Medical Group Plc operates as a medical device company that focuses on surgical endoscopy. The company is headquartered in Chepstow, Monmouthshire/Sir Fynwy and currently employs 245 full-time employees. The company went IPO on 2016-12-09. The firm focuses on the field of surgical endoscopy. The company is focused on the development and commercialization of minimally invasive electrosurgical devices. The firm has developed CROMA, which delivers bipolar radiofrequency (RF) energy for precise localized cutting and focused microwave (MW) energy for controlled coagulation and ablation through a single accessory port. The company has three initial areas of clinical focus, which include in the Gastrointestinal (GI) tract, soft tissue ablation (including but not limited to the liver, pancreas, kidney), and lung interventions for the resection and/or ablation of precancerous and cancerous lesions. The firm has four technology families, which include Speedboat, MicroBlate, SlypSeal and SpydrBlade.
Contact
IPO
Employees
Officers
The intrinsic value of one
CREO
stock under the Base Case scenario is
42.33
GBX.
Compared to the current market price of 34.34 GBX,
Creo Medical Group PLC
is
Undervalued by 19%.
You don't have any saved screeners yet
